Natixis Advisors LLC cut its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 66.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 51,620 shares of the company's stock after selling 102,097 shares during the period. Natixis Advisors LLC's holdings in Roivant Sciences were worth $611,000 at the end of the most recent quarter.
Several other institutional investors also recently added to or reduced their stakes in ROIV. GAMMA Investing LLC raised its position in Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock valued at $42,000 after purchasing an additional 1,288 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Roivant Sciences by 27.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock valued at $84,000 after acquiring an additional 1,507 shares in the last quarter. Quarry LP raised its holdings in shares of Roivant Sciences by 50.0% in the third quarter. Quarry LP now owns 7,500 shares of the company's stock valued at $87,000 after acquiring an additional 2,500 shares in the last quarter. Blue Trust Inc. lifted its stake in Roivant Sciences by 550.1% in the fourth quarter. Blue Trust Inc. now owns 7,879 shares of the company's stock worth $91,000 after acquiring an additional 6,667 shares during the period. Finally, HighTower Advisors LLC bought a new position in Roivant Sciences during the 4th quarter worth about $121,000. Hedge funds and other institutional investors own 64.76% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on ROIV shares. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a report on Tuesday, February 11th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $17.10.
Get Our Latest Report on ROIV
Roivant Sciences Stock Down 1.0 %
Shares of Roivant Sciences stock traded down $0.10 on Friday, reaching $10.38. The stock had a trading volume of 3,942,656 shares, compared to its average volume of 5,393,763. The stock has a market capitalization of $7.41 billion, a P/E ratio of -69.20 and a beta of 1.26. The company has a 50 day moving average price of $10.74 and a 200 day moving average price of $11.40. Roivant Sciences Ltd. has a 1 year low of $9.96 and a 1 year high of $13.06.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, analysts forecast that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Roivant Sciences news, CAO Rakhi Kumar sold 227,500 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the sale, the chief accounting officer now owns 163,264 shares of the company's stock, valued at approximately $1,702,843.52. The trade was a 58.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Eric Venker sold 218,041 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.42, for a total transaction of $2,271,987.22. Following the transaction, the chief operating officer now owns 896,869 shares in the company, valued at $9,345,374.98. The trade was a 19.56 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,573,245 shares of company stock worth $17,079,242 in the last ninety days. 7.90% of the stock is owned by insiders.
Roivant Sciences Company Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Recommended Stories
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
